# OnCo record paper-furlong-lancet-respir-med-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-furlong-lancet-respir-med-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-furlong-lancet-respir-med-2022" ;
  schema:name "Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study"@en ;
  schema:description "Published report from the FURLONG trial registered as NCT03787992, in The Lancet. Respiratory medicine (2022), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-furlong-lancet-respir-med-2022/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s2213-2600(22)00168-0>, <https://pubmed.ncbi.nlm.nih.gov/35662408/>, <https://europepmc.org/article/MED/35662408>, <https://clinicaltrials.gov/study/NCT03787992> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s2213-2600(22)00168-0> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Shi Y, Chen G, Wang X, et al." ;
  onco:trials <https://onco.cc/trials/furlong/> .